Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Pre-diabetes
Interventions
DRUG

(+)-Epicatechin

The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.

Trial Locations (1)

92161

VA San Diego Healthcare System, San Diego

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

San Diego Veterans Healthcare System

FED

collaborator

University of California, San Diego

OTHER

lead

Veterans Medical Research Foundation

OTHER

NCT02330276 - Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin | Biotech Hunter | Biotech Hunter